Komajda M, Eugène M, Evans J, Lecossier D, Grosgogeat Y
Nouv Presse Med. 1981 Apr 30;10(19):1587-90.
Nine patients with primary, non-obstructive myocardiopathy were treated during 6 months with captopril in daily doses of 75 to 225 mg. Early signs of haemodynamic improvement included significant increase in cardiac output (p Less Than 0.01) and stroke volume (p Less Than 0.01) and significant decrease in peripheral resistance (p Less Than 0.001) and pulmonary wedge pressure (p Less Than 0.001). These effects were sustained throughout treatment and were accompanied with noticeable improvement in the patients' functional status. Echocardiographic studies showed a reduction in the telesystolic (p Less Than 0.01) and telediastolic (p Less Than 0.05) diameters of the left ventricle after 6 months's treatment. The preejection period, calculated from phonomecanograms, was also significantly reduced. Plasma renin activity initially rose (p Less Than 0.01), then fell below pre-treatment values (p Less Than 0.02). Plasma aldosterone levels decreased (p Less Than 0.05), together with angiotensin-converting enzyme levels (p Less Than 0.05). Basal plasma renin activity correlated with both basal peripheral resistance (r = 0.72; p Less Than 0.02) and fall in peripheral resistance (r = 0.89; p Less Than 0.01). There was no tachyphylaxis nor evidence of blood, kidney or liver toxicity.
9例原发性非梗阻性心肌病患者接受了为期6个月的卡托普利治疗，日剂量为75至225毫克。血流动力学改善的早期迹象包括心输出量显著增加（p<0.01）、每搏输出量显著增加（p<0.01）、外周阻力显著降低（p<0.001）和肺楔压显著降低（p<0.001）。这些效应在整个治疗过程中持续存在，并伴随着患者功能状态的明显改善。超声心动图研究显示，治疗6个月后左心室收缩末期（p<0.01）和舒张末期（p<0.05）直径减小。根据心音图计算的射血前期也显著缩短。血浆肾素活性最初升高（p<0.01），然后降至治疗前值以下（p<0.02）。血浆醛固酮水平降低（p<0.05），同时血管紧张素转换酶水平也降低（p<0.05）。基础血浆肾素活性与基础外周阻力（r = 0.72；p<0.02）和外周阻力下降（r = 0.89；p<0.01）均相关。未出现快速耐受性，也没有血液、肾脏或肝脏毒性的证据。
